GeneDx Holdings Corp (NASDAQ:WGS) reported better-than-expected fourth-quarter financial results on Monday.
GeneDx reported quarterly earnings of 14 cents per share which beat the analyst consensus estimate of 11 cents per share. The company reported quarterly sales of $120.989 million which beat the analyst consensus estimate of $120.407 million.
GeneDx Holdings affirmed FY2026 sales guidance of $540.000 million to $555.000 million.
“The unmet need for early, accurate genomic diagnosis is enormous, and families are waiting far too long for answers. GeneDx is uniquely positioned to deliver for patients, clinicians, and partners — and our results demonstrate that. Our team is executing at the highest level, our platform continues to scale, and GeneDx InfinityTM gives us a compounding data advantage that strengthens with every test we run,” said Katherine Stueland, President and CEO of GeneDx. “The business has never been in a better position for continued growth and success. As we enter 2026, we will layer new growth drivers onto an already powerful foundation — expanding into large, underpenetrated markets where patients are waiting for a diagnosis that GeneDx can provide today.”
GeneDx shares fell 6.1% to trade at $81.82 on Tuesday.
These analysts made changes to their price targets on GeneDx following earnings announcement.
- BTIG analyst Mark Massaro maintained GeneDx with a Buy and lowered the price target from $200 to $170.
- Piper Sandler analyst David Westenberg maintained the stock with an Overweight rating and cut the price target from $160 to $130.
Considering buying WGS stock? Here’s what analysts think:
Photo via Shutterstock